Alphamab Oncology, established in 2015, is a biopharmaceutical company dedicated to the development, manufacturing and commercialization of cutting-edge innovative biotherapeutics for cancer treatment. On December 12, 2019, Alphamab Oncology was listed on the Main Board of the Hong Kong Stock Exchange, trading under the stock code 9966.
Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective and safe anti-tumor drugs with differentiated innovation and global competitiveness, delivering China-innovated cancer therapies to benefit patients worldwide.
The Company has established proprietary core technology platforms including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payload, dual-payload antibody conjugation, and subcutaneous high concentration formulation for biologics.
By leveraging its unique and leading proprietary technology platforms, Alphamab Oncology has established a differentiated and globally competitive product portfolio, covering cutting-edge areas such as antibody-drug conjugates (ADCs), bispecific antibodies, and single-domain antibodies.
Located in Suzhou Industrial Park, the R&D and industrialization base covers an area of 75 acres and was constructed in compliance with Good Manufacturing Practice (GMP) standards of the NMPA, FDA and EMA. The production lines are equipped with world-class equipment capable of meeting the large-scale manufacturing needs for a variety of biologics, including ADCs, both in the clinical and commercial stages.
